ArticleBiomolecules & biomedicine2025
Braden score at ICU admission predicts 30-day mortality in acute pancreatitis.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Braden score, a bedside assessment tool for evaluating the risk of pressure ulcers and frailty, may identify vulnerabilities pertinent to outcomes in acute pancreatitis (AP). However, its prognostic significance in this context remains uncertain. This study aimed to determine whether the Braden score at admission predicts all-cause mortality in intensive care unit (ICU) patients with AP and whether it provides additional value to existing clinical models. In a retrospective single-center cohort study utilizing data from MIMIC-IV v3.1 (2008-2022), we included 1,985 adults diagnosed with AP. We analyzed the Braden score as both a continuous variable and a dichotomous variable (high-risk: ≤15 vs. low-risk: >15), with 30-day mortality as the primary endpoint (with secondary endpoints at 90, 180, and 360 days). Our methodology encompassed Kaplan-Meier analysis, multivariable Cox regression, restricted cubic splines, receiver operating characteristic curves, and calibration assessments. By the 30-day mark, a total of 230 deaths were recorded (11.6%). Each 1-point increase in the Braden score correlated with a 7.7% reduction in mortality risk (HR 0.923, 95% CI 0.873-0.976; p=0.005). Furthermore, patients categorized as low-risk experienced lower mortality rates compared to high-risk patients (HR 0.688, 95% CI 0.501-0.945; p=0.021). The discrimination capability at 30 days was moderate (AUC 0.67, 95% CI 0.63-0.71), with an optimal cutoff score of 15 (sensitivity 61%, specificity 65%) and good calibration; however, performance diminished over longer durations. Incorporating the Braden score into a baseline clinical model enhanced predictive accuracy (AUC 0.712 vs. 0.647; NRI 0.235; IDI 0.040; all p<0.001). The Braden score at ICU admission is independently associated with 30-day mortality in patients with AP, providing moderate, well-calibrated predictions and significant incremental value. This supports its application as an early and straightforward tool for risk stratification, pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.